UNIGE document Scientific Article
previous document  unige:47551  next document
add to browser collection

European perspective for effective cancer drug development

Lacombe, Denis
Tejpar, Sabine
Salgado, Roberto
Cardoso, Fatima
Golfinopoulos, Vassilis
Aust, Daniela
Folprecht, Gunnar
show hidden authors show all authors [1 - 9]
Published in Nature Reviews Clinical Oncology 1759-4782]. 2014, vol. 11, no. 8, p. 492-8
Abstract Health systems and the clinical research landscape evolve continuously owing to increased risk aversion, scrutiny by funding bodies, and costs of clinical trials. In this context, however, current drug development procedures are far from optimal, as exemplified by the late-stage failure of several drugs. The identification of new drugs urgently requires approaches based on a solid understanding of cancer biology, and that will support the design of robust confirmatory trials. The complexity and the costs of drug development are now beyond the knowledge and operational capacity of single organisations, therefore, a drastic deviation from the traditional path of drug discovery and new forms of multidisciplinary partnerships are needed to succeed in this sector. The European Organisation for Research and Treatment of Cancer (EORTC) proposes the use of collaborative molecular screening platforms (CMSPs) as a new approach to tackle this issue. These CMSPs have the advantage of optimizing the expertise of several partners and combining efforts alongside with cost-sharing models for efficient patient selection. This article describes some of the challenges to advancing drug development and improving medical treatments and how these hurdles can be overcome.
Keywords Antineoplastic Agents/therapeutic useDrug DiscoveryEuropeHumansNeoplasms/drug therapy
PMID: 24935010
Full text
Article (Published version) (1.7 MB) - document accessible for UNIGE members only Limited access to UNIGE
Research group Groupe Roth Arnaud (oncologie) (285)
(ISO format)
LACOMBE, Denis et al. European perspective for effective cancer drug development. In: Nature Reviews Clinical Oncology 1759-4782] , 2014, vol. 11, n° 8, p. 492-8. doi: 10.1038/nrclinonc.2014.98 https://archive-ouverte.unige.ch/unige:47551

572 hits

0 download


Deposited on : 2015-03-04

Export document
Format :
Citation style :